31 August 2022 | Technology

Moderna sues Pfizer for patent infringement

Last week, Moderna filed a claim for patent infringement against Pfizer and BioNTech. The companies copied messenger RNA technology developed and researched by Moderna, officials said. As a result, Moderna filed a lawsuit, and its amount has not yet been reported.

The COVID-19 vaccines designed by Pfizer and BioNTech were created with innovative mRNA technology patented by Moderna back in 2010-2016. 

Moderna, in turn, doesn’t plan to file patents for Spikevax — its proprietary elaboration effort. The purpose is quite obvious: to create vaccine analogues in third world countries. This move would be impossible with a patent. Moderna is also not going to file a lawsuit demanding compensation for lost profits. 

And that brings the company to its ultimate purpose. Moderna intends to achieve a ban on using mRNA in Pfizer and BioNTech vaccines. So that the sale of the most popular COVID-19 drug, Comirnaty will be suspended.

In the midst of the pandemic, Moderna vowed not to pursue full patent enforcement from regulators. In this sense, Pfizer has been considered as the largest supplier of COVID-19 vaccines, earning more than $20 billion last year. 

In case the court takes the plaintiff side, Pfizer could possibly lose half of its proceeds from the Comirnaty sales that equals to a quarter of its annual budget. But the verdict can take a long time. This may affect investors of pharmaceutical enterprises. As when patent disputes arise, the shares’ value of opposing firms often decreases.

The situation is also ambiguous for Moderna. An attempt to drive competitors out of the market may indicate that other products in development have fallen short of the company's expectations. Thus, the Spikevax vaccine based on messenger RNA is likely to become the main profit source for the coming years.

Anyway, Moderna isn’t the only developer of mRNA technology. The patent belongs to the firm, but the key research facility is the U.S. National Institutes of Health. The company is also in a public dispute with this healthcare department.


Company MarketCheese
Period: 15.11.2024 Expectation: 700 pips
Surging AUDCAD confirms advantage of bulls
08 November 2024 57
AntonVolkov
AntonVolkov

Listed among the best MarketCheese authors
3rd in the segment "Currencies"
Brent sell
Period: 15.11.2024 Expectation: 465 pips
Brent oil prices may decline in short-term under global changes
08 November 2024 70
Alexandra_Belova
Alexandra_Belova

Listed among the best MarketCheese authors
1st in the segments "Crypto" and "Oil and gas"
2nd in the segment "Currencies"
Period: 12.11.2024 Expectation: 2740 pips
USDJPY maintains uptrend with the nearest target at 156.80
07 November 2024 95
Elena_Dorokhina
Elena_Dorokhina

Listed among the best MarketCheese authors
1st in the segments "Currencies" and "Metals"
Period: 11.11.2024 Expectation: 500 pips
US election results send EURUSD to summer lows
06 November 2024 100
AntonVolkov
AntonVolkov

Listed among the best MarketCheese authors
3rd in the segment "Currencies"
Period: 01.12.2024 Expectation: 1660 pips
Strong dollar supports USDCAD growth amid soft monetary policy of the Bank of Canada
06 November 2024 71
Elena_Dorokhina
Elena_Dorokhina

Listed among the best MarketCheese authors
1st in the segments "Currencies" and "Metals"
Period: 08.11.2024 Expectation: 600 pips
GBPUSD rebounds towards the level of 1.304
05 November 2024 94
AntonVolkov
AntonVolkov

Listed among the best MarketCheese authors
3rd in the segment "Currencies"
Go to forecasts